MinnesotaCancer Quality Measures Compared to Achievable Benchmarks

The NHQDR quality measures specific to Cancer are compared to achievable benchmarks, which are derived from the top-performing States. Better performance of a State can mean higher or lower values of a measure, depending on the desired outcome. For example, low values are desirable for measures such as infant mortality, whereas high values are desirable for measures such as preventative screening. The categories of achievement have been standardized across the measure definitions so that:

 
Far away from benchmark - a State's value for a measure has not achieved 50% of the benchmark.
 
Close to benchmark - a State's value for a measure is between 50% and 90% of a benchmark (i.e., worse than the benchmark but has achieved at least half of the benchmark but not as much as 90% of a benchmark).
 
Achieved benchmark or better - a State's value for a measure is no worse than 90% of the benchmark value, the measure has achieved the benchmark. This category also includes the case in which the measure’s value is equal to or better than the benchmark.
Measures That Achieved Benchmark or Better
Measure Estimate Benchmark Distance to Benchmark
Breast cancer deaths per 100,000 female population per year 17.0 17.8 Achieved: 4% better
Women with clinical Stage I-IIb breast cancer who received axillary node dissection or sentinel lymph node biopsy (SLNB) at the time of surgery (lumpectomy or mastectomy) 95.1 96.8 1.8%
Women under age 70 treated for breast cancer with breast-conserving surgery who received radiation therapy to the breast within 1 year of diagnosis 94.4 97.0 2.7%
Patients with colon cancer who received surgical resection of colon cancer that included at least 12 lymph nodes pathologically examined 92.5 95.3 2.9%
Colorectal cancer deaths per 100,000 population per year 12.5 11.5 8.3%
Measures That Are Close to Benchmark
Measure Estimate Benchmark Distance to Benchmark
Breast cancer diagnosed at advanced stage (regional, distant stage, or local stage with tumor greater than 2 cm) per 100,000 women age 40 and over 81.0 72.8 11.3%
Cervical cancer diagnosed at advanced stage (all invasive tumors) per 100,000 women age 20 and over 8.7 7.6 15.1%
Colorectal cancer diagnosed at advanced stage (tumors diagnosed at regional or distant stage) per 100,000 population age 50 and over 58.4 47.2 23.8%
Lung cancer deaths per 100,000 population per year 34.9 27.5 27.1%
Measures With No Available Benchmark Information or Supplemental Measures
Measure Estimate Benchmark Distance to Benchmark
Composite measure: Cancer deaths per 100,000 population per year for all cancers 148.6
Combination chemotherapy was recommended or administered within 4 months of diagnosis for women under 70 with AJCC T1cN0MO or Stage IB-III hormone receptor negative breast cancer 97.7
Adjuvant chemotherapy was recommended or administered within 4 months of diagnosis for patients under the age of 80 with AJCC Stage III lymph node positive colon cancer 93.8
Tamoxifen or third generation aromatase inhibitor was recommended or administered within 1 year of diagnosis for women with AJCC T1cN0M0 or stage IB to stage III hormone receptor-positive breast cancer 88.8
Radiation therapy was recommended or administered following any mastectomy within 1 year of diagnosis of breast cancer for women with 4 positive regional lymph nodes 94.2
Adults treated at a HRSA supported health centers with appropriate screening for colorectal cancer 44.9